This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186Re) Obisbemeda. “This continuing agreement with Telix ...
D Five-year renewable agreement secures reliable cGMP rhenium-186 (Re-186) supply for late-stage clinical and commercial forecastsAUSTIN, Texas, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics ...
Obtained agreement from FDA to initiate a Phase 1 trial evaluating multiple doses of Rhenium (186 Re) Obisbemeda for the treatment of patients with leptomeningeal metastases (LM) Presented ...
Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE ...
Company to present ReSPECT-LM Phase 1 trial data on Rhenium (186Re) Obisbemeda with a focus on treating leptomeningeal metastases (LM) in breast cancer patients AUSTIN, Texas, Dec. 04, 2024 (GLOBE ...
This MSA secures a reliable supply of cGMP Re-186, the radioisotope used in Plus Therapeutics’ lead radiotherapeutic candidate Rhenium (186 Re) Obisbemeda. “This continuing agreement with Telix ...
The data were presented in a session titled, “Rhenium (186 Re) Obisbemeda (rhenium nanoliposome, 186 RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose escalation ...
Receives FDA agreement to initiate the ReSPECT-LM Phase 1 multiple administration dose escalation trial of Rhenium (186Re) Obisbemeda for LM AUSTIN, Texas, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Plus ...
The data were presented in a session titled, “Rhenium (186 Re) Obisbemeda (rhenium nanoliposome, 186 RNL) for the treatment of leptomeningeal metastases (LM): Summary of the Phase 1 dose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback